Julia V. Shingleton, Brooke W. Stapleton, Aisling P. Kelly, Robyn L. Ward, Cynthia L. Lean, Shelley A. Rushton, Tracey A. O'Brien
{"title":"eviQ 癌症治疗在线：提供循证信息，改善癌症患者的治疗效果","authors":"Julia V. Shingleton, Brooke W. Stapleton, Aisling P. Kelly, Robyn L. Ward, Cynthia L. Lean, Shelley A. Rushton, Tracey A. O'Brien","doi":"10.1111/ajco.14067","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>To understand the current usage of eviQ Cancer Treatments Online (www.eviQ.org.au), an Australian, open-access website providing evidence-based and consensus-driven cancer treatment protocols and information, and the extent to which it is meeting its intended outcomes and providing value to its users.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A mixed-method evaluation was conducted in 2020−2022 which included a review of key program documentation and website usage data, and delivery of a focused online survey to its users.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In 2022, 329 clinicians representing all Australian states and territories contributed to eviQ content development and review. eviQ content continues to grow with a 15.2% increase in total content from 2019 to 2022.</p>\n \n <p> eviQ website users continue to grow with 90,000 total monthly users in 2022, representing a 166% increase from 2018. The proportion of international users compared to Australian users continues to grow with 57% of total users in Australia and 43% international in 2022.</p>\n \n <p>Of 466 survey responses, the most cited reason for eviQ use was <i>for information on side effects/toxicity</i> (67%). Ninety-three percent (93%) of respondents either agreed or strongly agreed that eviQ contributed to both <i>health professionals providing the best evidence-based treatment and care</i> and <i>improving the standardization of treatment and care provided</i>.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p> eviQ is embedded in Australian clinical practice, highly valued, and relied upon by users. Users agree that eviQ has a positive impact on patients by supporting the delivery of evidence-based treatment and that eviQ contributed to patients’ improved health outcomes and quality of life. eviQ's increasing international usage should be explored.</p>\n </section>\n </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"eviQ Cancer Treatments Online: Providing evidence-based information to improve cancer patient outcomes\",\"authors\":\"Julia V. Shingleton, Brooke W. Stapleton, Aisling P. Kelly, Robyn L. Ward, Cynthia L. Lean, Shelley A. Rushton, Tracey A. O'Brien\",\"doi\":\"10.1111/ajco.14067\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Aim</h3>\\n \\n <p>To understand the current usage of eviQ Cancer Treatments Online (www.eviQ.org.au), an Australian, open-access website providing evidence-based and consensus-driven cancer treatment protocols and information, and the extent to which it is meeting its intended outcomes and providing value to its users.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>A mixed-method evaluation was conducted in 2020−2022 which included a review of key program documentation and website usage data, and delivery of a focused online survey to its users.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>In 2022, 329 clinicians representing all Australian states and territories contributed to eviQ content development and review. eviQ content continues to grow with a 15.2% increase in total content from 2019 to 2022.</p>\\n \\n <p> eviQ website users continue to grow with 90,000 total monthly users in 2022, representing a 166% increase from 2018. The proportion of international users compared to Australian users continues to grow with 57% of total users in Australia and 43% international in 2022.</p>\\n \\n <p>Of 466 survey responses, the most cited reason for eviQ use was <i>for information on side effects/toxicity</i> (67%). Ninety-three percent (93%) of respondents either agreed or strongly agreed that eviQ contributed to both <i>health professionals providing the best evidence-based treatment and care</i> and <i>improving the standardization of treatment and care provided</i>.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p> eviQ is embedded in Australian clinical practice, highly valued, and relied upon by users. Users agree that eviQ has a positive impact on patients by supporting the delivery of evidence-based treatment and that eviQ contributed to patients’ improved health outcomes and quality of life. eviQ's increasing international usage should be explored.</p>\\n </section>\\n </div>\",\"PeriodicalId\":8633,\"journal\":{\"name\":\"Asia-Pacific journal of clinical oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-04-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asia-Pacific journal of clinical oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ajco.14067\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ajco.14067","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
eviQ Cancer Treatments Online: Providing evidence-based information to improve cancer patient outcomes
Aim
To understand the current usage of eviQ Cancer Treatments Online (www.eviQ.org.au), an Australian, open-access website providing evidence-based and consensus-driven cancer treatment protocols and information, and the extent to which it is meeting its intended outcomes and providing value to its users.
Methods
A mixed-method evaluation was conducted in 2020−2022 which included a review of key program documentation and website usage data, and delivery of a focused online survey to its users.
Results
In 2022, 329 clinicians representing all Australian states and territories contributed to eviQ content development and review. eviQ content continues to grow with a 15.2% increase in total content from 2019 to 2022.
eviQ website users continue to grow with 90,000 total monthly users in 2022, representing a 166% increase from 2018. The proportion of international users compared to Australian users continues to grow with 57% of total users in Australia and 43% international in 2022.
Of 466 survey responses, the most cited reason for eviQ use was for information on side effects/toxicity (67%). Ninety-three percent (93%) of respondents either agreed or strongly agreed that eviQ contributed to both health professionals providing the best evidence-based treatment and care and improving the standardization of treatment and care provided.
Conclusion
eviQ is embedded in Australian clinical practice, highly valued, and relied upon by users. Users agree that eviQ has a positive impact on patients by supporting the delivery of evidence-based treatment and that eviQ contributed to patients’ improved health outcomes and quality of life. eviQ's increasing international usage should be explored.
期刊介绍：
Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
